Abstract
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-α4 integrin; vedolizumab, anti-α4β7 integrin), and several other agents in the same class currently under development.
Original language | English (US) |
---|---|
Pages (from-to) | 581-601 |
Number of pages | 21 |
Journal | Gastroenterology Clinics of North America |
Volume | 43 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2014 |
Keywords
- Chemokine receptors
- Crohn disease
- Etrolizumab
- Inflammatory bowel disease
- Integrins
- Natalizumab
- Ulcerative colitis
- Vedolizumab
ASJC Scopus subject areas
- Gastroenterology